Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era
机构:[1]Department of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]West China School of Medicine, Sichuan University, Chengdu, China四川大学华西医院[3]Department of Hematology, Clinical Medical College & Afliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China[4]Department of Hematology, Chengdu Third People’s Hospital, Chengdu, Sichuan, China
第一作者机构:[1]Department of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Yan,Zhang Xinyi,Zou Zhongqing,et al.Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era[J].Clinical And Experimental Medicine.2024,24(1):215.doi:10.1007/s10238-024-01481-2.
APA:
Li Yan,Zhang Xinyi,Zou Zhongqing,Xiong Yanqiu,Gu Xinyuan...&Niu Ting.(2024).Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.Clinical And Experimental Medicine,24,(1)
MLA:
Li Yan,et al."Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era".Clinical And Experimental Medicine 24..1(2024):215